AMGN

Amgen’s moat is built on a diversified biologics portfolio, global manufacturing scale, and deep commercial access, which helps offset inevitable patent cliffs. The 2023 Horizon acquisition broadened the rare-disease platform (e.g., TEPEZZA, KRYSTEXXA, UPLIZNA), while newer launches like IMDELLTRA and biosimilars (PAVBLU, WEZLANA) add growth vectors. Industry-wide, U.S. pricing pressure (IRA/Medicare dynamics) is increasing the premium on differentiated outcomes and pipeline productivity.

Financially, FY2025 revenue rose 10% to $36.8B and non-GAAP EPS grew 10% to $21.84, with GAAP operating margin at 25.8%. Free cash flow was $8.1B in 2025 (down from $10.4B in 2024) amid higher capex, while operating cash flow was $10.0B; management also retired $6.0B of debt. At roughly 22.7x P/E (Q4 2025) and an annual dividend run-rate of $10.08 (~2.8–2.9% yield near recent prices), valuation looks reasonable for a low-beta large-cap, but not a deep-value entry.

Over the next 12 months, the stock should trade on execution versus 2026 guidance (revenue $37.0B–$38.4B; non-GAAP EPS $21.60–$23.00) and evidence that newer growth brands can outpace declines. Key risks are faster-than-expected erosion in bone health (Prolia/XGEVA biosimilar competition) and further net price pressure in major products, including Repatha and Enbrel. A near-term catalyst is Q1 2026 earnings on April 30, 2026, which can reset sentiment on the 2026 trajectory.

Recommendation: HOLD. The cash-generation and dividend support are strong, but the balance of 2026 growth versus accelerating biosimilar/price headwinds looks fairly priced after the recent range, limiting upside without clearer pipeline-to-commercial inflection.